Cargando…

ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?

The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mejzini, Rita, Flynn, Loren L., Pitout, Ianthe L., Fletcher, Sue, Wilton, Steve D., Akkari, P. Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909825/
https://www.ncbi.nlm.nih.gov/pubmed/31866818
http://dx.doi.org/10.3389/fnins.2019.01310
_version_ 1783479003804336128
author Mejzini, Rita
Flynn, Loren L.
Pitout, Ianthe L.
Fletcher, Sue
Wilton, Steve D.
Akkari, P. Anthony
author_facet Mejzini, Rita
Flynn, Loren L.
Pitout, Ianthe L.
Fletcher, Sue
Wilton, Steve D.
Akkari, P. Anthony
author_sort Mejzini, Rita
collection PubMed
description The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disease-modifying genes identified, etiology remains unexplained and treatment options remain limited for the majority of ALS patients. Various factors have contributed to the slow progress in understanding and developing therapeutics for this disease. Here, we review the genetic basis of ALS, highlighting factors that have contributed to the elusiveness of genetic heritability. The most commonly mutated ALS-linked genes are reviewed with an emphasis on disease-causing mechanisms. The cellular processes involved in ALS pathogenesis are discussed, with evidence implicating their involvement in ALS summarized. Past and present therapeutic strategies and the benefits and limitations of the model systems available to ALS researchers are discussed with future directions for research that may lead to effective treatment strategies outlined.
format Online
Article
Text
id pubmed-6909825
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69098252019-12-20 ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Mejzini, Rita Flynn, Loren L. Pitout, Ianthe L. Fletcher, Sue Wilton, Steve D. Akkari, P. Anthony Front Neurosci Neuroscience The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disease-modifying genes identified, etiology remains unexplained and treatment options remain limited for the majority of ALS patients. Various factors have contributed to the slow progress in understanding and developing therapeutics for this disease. Here, we review the genetic basis of ALS, highlighting factors that have contributed to the elusiveness of genetic heritability. The most commonly mutated ALS-linked genes are reviewed with an emphasis on disease-causing mechanisms. The cellular processes involved in ALS pathogenesis are discussed, with evidence implicating their involvement in ALS summarized. Past and present therapeutic strategies and the benefits and limitations of the model systems available to ALS researchers are discussed with future directions for research that may lead to effective treatment strategies outlined. Frontiers Media S.A. 2019-12-06 /pmc/articles/PMC6909825/ /pubmed/31866818 http://dx.doi.org/10.3389/fnins.2019.01310 Text en Copyright © 2019 Mejzini, Flynn, Pitout, Fletcher, Wilton and Akkari. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Mejzini, Rita
Flynn, Loren L.
Pitout, Ianthe L.
Fletcher, Sue
Wilton, Steve D.
Akkari, P. Anthony
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
title ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
title_full ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
title_fullStr ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
title_full_unstemmed ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
title_short ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
title_sort als genetics, mechanisms, and therapeutics: where are we now?
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909825/
https://www.ncbi.nlm.nih.gov/pubmed/31866818
http://dx.doi.org/10.3389/fnins.2019.01310
work_keys_str_mv AT mejzinirita alsgeneticsmechanismsandtherapeuticswherearewenow
AT flynnlorenl alsgeneticsmechanismsandtherapeuticswherearewenow
AT pitoutianthel alsgeneticsmechanismsandtherapeuticswherearewenow
AT fletchersue alsgeneticsmechanismsandtherapeuticswherearewenow
AT wiltonsteved alsgeneticsmechanismsandtherapeuticswherearewenow
AT akkaripanthony alsgeneticsmechanismsandtherapeuticswherearewenow